97 related articles for article (PubMed ID: 20138374)
1. The TLR7 agonist, imiquimod, increases IFN-beta production and reduces the severity of experimental autoimmune encephalomyelitis.
O'Brien K; Fitzgerald D; Rostami A; Gran B
J Neuroimmunol; 2010 Apr; 221(1-2):107-11. PubMed ID: 20138374
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
3. Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis.
Khorooshi R; Mørch MT; Holm TH; Berg CT; Dieu RT; Dræby D; Issazadeh-Navikas S; Weiss S; Lienenklaus S; Owens T
Acta Neuropathol; 2015 Jul; 130(1):107-18. PubMed ID: 25869642
[TBL] [Abstract][Full Text] [Related]
4. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
5. Effects of human recombinant-interferon β in experimental autoimmune encephalomyelitis in guinea pigs.
Aritake K; Koh CS; Inoue A; Yabuuchi F; Kitagaki K; Ikoma Y; Hayashi S
Pharm Biol; 2010 Nov; 48(11):1273-9. PubMed ID: 20795785
[TBL] [Abstract][Full Text] [Related]
6. 17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Matejuk A; Adlard K; Zamora A; Silverman M; Vandenbark AA; Offner H
J Neurosci Res; 2001 Sep; 65(6):529-42. PubMed ID: 11550221
[TBL] [Abstract][Full Text] [Related]
7. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
8. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
9. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis.
Aminian A; Noorbakhsh F; Ghazi-Khansari M; Kafami L; Javadi S; Hassanzadeh G; Rahimian R; Dehpour AR; Mehr SE
Neuroscience; 2013 Sep; 248():299-306. PubMed ID: 23774631
[TBL] [Abstract][Full Text] [Related]
10. IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Cheng W; Zhao Q; Xi Y; Li C; Xu Y; Wang L; Niu X; Wang Z; Chen G
Mol Immunol; 2015 Mar; 64(1):152-62. PubMed ID: 25433436
[TBL] [Abstract][Full Text] [Related]
11. Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis.
Suardíaz M; Clemente D; Marin-Bañasco C; Orpez T; Hurtado-Guerrero I; Pavía J; Pinto-Medel MJ; De Castro F; Leyva L; Fernández O; Oliver B
Neuropharmacology; 2016 Nov; 110(Pt A):480-492. PubMed ID: 27452720
[TBL] [Abstract][Full Text] [Related]
12. The TLR7 agonist Imiquimod promote the immunogenicity of mesenchymal stem cells.
Zhang L; Liu D; Pu D; Wang Y; Li L; He Y; Li Y; Li L; Li W
Biol Res; 2015 Jan; 48(1):6. PubMed ID: 25654296
[TBL] [Abstract][Full Text] [Related]
13. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
[TBL] [Abstract][Full Text] [Related]
15. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Wang Y; Mei Y; Feng D; Xu L
J Neurosci Res; 2008 Aug; 86(11):2441-9. PubMed ID: 18438925
[TBL] [Abstract][Full Text] [Related]
16. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
17. Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta.
Touil T; Fitzgerald D; Zhang GX; Rostami A; Gran B
J Immunol; 2006 Dec; 177(11):7505-9. PubMed ID: 17114417
[TBL] [Abstract][Full Text] [Related]
18. C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis.
Moriguchi K; Miyamoto K; Tanaka N; Ueno R; Nakayama T; Yoshie O; Kusunoki S
J Neuroimmunol; 2016 Feb; 291():54-8. PubMed ID: 26857495
[TBL] [Abstract][Full Text] [Related]
19. Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms.
Dutra RC; de Souza PR; Bento AF; Marcon R; Bicca MA; Pianowski LF; Calixto JB
Biochem Pharmacol; 2012 Feb; 83(4):531-42. PubMed ID: 22155310
[TBL] [Abstract][Full Text] [Related]
20. Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice.
Stoye D; Schubert C; Goihl A; Guttek K; Reinhold A; Brocke S; Grüngreiff K; Reinhold D
Biometals; 2012 Jun; 25(3):529-39. PubMed ID: 22350510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
